×
About 143,524 results

ALLMedicine™ Schizophrenia Center

Research & Reviews  67,889 results

14-3-3 Proteins at the Crossroads of Neurodevelopment and Schizophrenia.
https://doi.org/10.1080/15622975.2021.1925585
The World Journal of Biological Psychiatry : the Official... Antunes ASLM, Saia-Cereda VM et. al.

May 6th, 2021 - The 14-3-3 family comprises multifunctional proteins that play a role in neurogenesis, neuronal migration, neuronal differentiation, synaptogenesis and dopamine synthesis. 14-3-3 members function as adaptor proteins and impact a wide variety of ce...

Abnormal prediction error processing in schizophrenia and depression.
https://doi.org/10.1002/hbm.25453
Human Brain Mapping; Yaple ZA, Tolomeo S et. al.

May 6th, 2021 - To make adaptive decisions under uncertainty, individuals need to actively monitor the discrepancy between expected outcomes and actual outcomes, known as prediction errors. Reward-based learning deficits have been shown in both depression and sch...

Suicide rates among people with serious mental illness: a systematic review and meta-an...
https://doi.org/10.1017/S0033291721001549
Psychological Medicine; Fu XL, Qian Y et. al.

May 6th, 2021 - People with serious mental illness are at great risk of suicide, but little is known about the suicide rates among this population. We aimed to quantify the suicide rates among people with serious mental illness (bipolar disorder, major depression...

Theory of Mind in Offending: A Systematic Review.
https://doi.org/10.1177/15248380211013143
Trauma, Violence & Abuse; Karoğlu N, Ferguson HJ et. al.

May 6th, 2021 - Theory of mind (ToM) impairment is associated with poor social functioning in some psychological disorders (e.g., autism and schizophrenia). ToM deficits have also been linked with offending behavior in the theoretical literature. However, no revi...

Decision making under ambiguity and risk in adolescent-onset schizophrenia.
https://doi.org/10.1186/s12888-021-03230-1 10.1586/14737175.4.1.53 10.1007/s00787-005-0515-2 10.1016/j.jaac.2016.12.013 10.1517/14656566.9.12.2053 10.1038/nrn2513 10.1016/j.nbd.2018.06.020 10.1016/S0140-6736(13)62036-X 10.1016/j.rcpeng.2018.06.004 10.1016/j.euroneuro.2015.02.003 10.4088/JCP.12m07632 10.1002/wps.20056 10.1016/j.drugalcdep.2019.107593 10.1016/S0140-1971(03)00036-8 10.1038/nrn2374 10.1073/pnas.1605619113 10.1016/j.bandc.2003.04.001 10.1016/j.neunet.2006.03.001 10.1016/0010-0277(94)90018-3 10.1016/j.pnpbp.2014.09.005 10.1093/arclin/acy036 10.1016/j.psychres.2006.02.001 10.1016/j.heliyon.2019.e02767 10.1016/j.jbtep.2016.08.004 10.1016/j.jpsychires.2015.04.007 10.3389/fnbeh.2014.00417 10.1523/JNEUROSCI.0989-14.2014 10.1016/j.schres.2018.11.004 10.1093/schbul/sbn068 10.1007/s00406-012-0330-y 10.1080/13803390500507196 10.1037/a0026342 10.1080/13803395.2014.918091 10.1007/s10899-018-9796-5 10.1016/j.schres.2006.02.028 10.1016/j.yebeh.2019.106548 10.1016/j.jocn.2011.11.039 10.1111/j.2044-8341.1959.tb00467.x 10.1136/jnnp.23.1.56 10.1093/schbul/13.2.261 10.1016/0028-3932(71)90067-4 10.1016/j.pnpbp.2014.10.007 10.1038/nn.3177 10.1093/schbul/sbw060 10.1001/jamapsychiatry.2018.1973 10.1523/JNEUROSCI.1062-06.2006 10.1016/j.neubiorev.2018.06.004 10.1007/s10802-016-0249-2 10.1017/S1355617719000341 10.1007/s00234-017-1949-1 10.1016/S0278-2626(03)00275-6 10.1017/S0033291717001374 10.1590/1980-57642018dn13-010013 10.3389/fpsyg.2020.00694 10.1001/archgenpsychiatry.2011.1269 10.1037/abn0000240
BMC Psychiatry; Li D, Zhang F et. al.

May 5th, 2021 - Numerous studies have identified impaired decision making (DM) under both ambiguity and risk in adult patients with schizophrenia. However, the assessment of DM in patients with adolescent-onset schizophrenia (AOS) has been challenging as a result...

see more →

Guidelines  45 results

The American Psychiatric Association Practice Guideline for the Treatment of Patients W...
https://doi.org/10.1176/appi.ajp.2020.177901
The American Journal of Psychiatry; Keepers GA, Fochtmann LJ et. al.

Sep 1st, 2020 - The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.|2020|Keepers GA,Fochtmann LJ,Anzia JM,Benjamin S,Lyness JM,|methods,methods,methods,classification,therapeutic use,diagnosis,therapy,

CAPLYTA® (lumateperone) | Now Approved | caplyta.com‎
https://www.caplyta.com/‎

Jan 13th, 2020 - Learn about a new treatment. See full safety information, PI, and boxed warning. Get information about this orally administered capsule. Press Release. Prescribing Information. MOA. Important Safety Info. Dosing & Administration.

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated r...
https://doi.org/10.1177/0269881119889296
Journal of Psychopharmacology (Oxford, England); Barnes TR, Drake R et. al.

Dec 12th, 2019 - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, i...

Cannabidiol as a potential treatment for psychosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843725/
Therapeutic Advances in Psychopharmacology; Davies C,et al

Nov 7th, 2019 - Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treat...

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch fo...

see more →

Drugs  1,689 results see all →

Clinicaltrials.gov  71,183 results

14-3-3 Proteins at the Crossroads of Neurodevelopment and Schizophrenia.
https://doi.org/10.1080/15622975.2021.1925585
The World Journal of Biological Psychiatry : the Official... Antunes ASLM, Saia-Cereda VM et. al.

May 6th, 2021 - The 14-3-3 family comprises multifunctional proteins that play a role in neurogenesis, neuronal migration, neuronal differentiation, synaptogenesis and dopamine synthesis. 14-3-3 members function as adaptor proteins and impact a wide variety of ce...

Abnormal prediction error processing in schizophrenia and depression.
https://doi.org/10.1002/hbm.25453
Human Brain Mapping; Yaple ZA, Tolomeo S et. al.

May 6th, 2021 - To make adaptive decisions under uncertainty, individuals need to actively monitor the discrepancy between expected outcomes and actual outcomes, known as prediction errors. Reward-based learning deficits have been shown in both depression and sch...

Suicide rates among people with serious mental illness: a systematic review and meta-an...
https://doi.org/10.1017/S0033291721001549
Psychological Medicine; Fu XL, Qian Y et. al.

May 6th, 2021 - People with serious mental illness are at great risk of suicide, but little is known about the suicide rates among this population. We aimed to quantify the suicide rates among people with serious mental illness (bipolar disorder, major depression...

Theory of Mind in Offending: A Systematic Review.
https://doi.org/10.1177/15248380211013143
Trauma, Violence & Abuse; Karoğlu N, Ferguson HJ et. al.

May 6th, 2021 - Theory of mind (ToM) impairment is associated with poor social functioning in some psychological disorders (e.g., autism and schizophrenia). ToM deficits have also been linked with offending behavior in the theoretical literature. However, no revi...

Decision making under ambiguity and risk in adolescent-onset schizophrenia.
https://doi.org/10.1186/s12888-021-03230-1 10.1586/14737175.4.1.53 10.1007/s00787-005-0515-2 10.1016/j.jaac.2016.12.013 10.1517/14656566.9.12.2053 10.1038/nrn2513 10.1016/j.nbd.2018.06.020 10.1016/S0140-6736(13)62036-X 10.1016/j.rcpeng.2018.06.004 10.1016/j.euroneuro.2015.02.003 10.4088/JCP.12m07632 10.1002/wps.20056 10.1016/j.drugalcdep.2019.107593 10.1016/S0140-1971(03)00036-8 10.1038/nrn2374 10.1073/pnas.1605619113 10.1016/j.bandc.2003.04.001 10.1016/j.neunet.2006.03.001 10.1016/0010-0277(94)90018-3 10.1016/j.pnpbp.2014.09.005 10.1093/arclin/acy036 10.1016/j.psychres.2006.02.001 10.1016/j.heliyon.2019.e02767 10.1016/j.jbtep.2016.08.004 10.1016/j.jpsychires.2015.04.007 10.3389/fnbeh.2014.00417 10.1523/JNEUROSCI.0989-14.2014 10.1016/j.schres.2018.11.004 10.1093/schbul/sbn068 10.1007/s00406-012-0330-y 10.1080/13803390500507196 10.1037/a0026342 10.1080/13803395.2014.918091 10.1007/s10899-018-9796-5 10.1016/j.schres.2006.02.028 10.1016/j.yebeh.2019.106548 10.1016/j.jocn.2011.11.039 10.1111/j.2044-8341.1959.tb00467.x 10.1136/jnnp.23.1.56 10.1093/schbul/13.2.261 10.1016/0028-3932(71)90067-4 10.1016/j.pnpbp.2014.10.007 10.1038/nn.3177 10.1093/schbul/sbw060 10.1001/jamapsychiatry.2018.1973 10.1523/JNEUROSCI.1062-06.2006 10.1016/j.neubiorev.2018.06.004 10.1007/s10802-016-0249-2 10.1017/S1355617719000341 10.1007/s00234-017-1949-1 10.1016/S0278-2626(03)00275-6 10.1017/S0033291717001374 10.1590/1980-57642018dn13-010013 10.3389/fpsyg.2020.00694 10.1001/archgenpsychiatry.2011.1269 10.1037/abn0000240
BMC Psychiatry; Li D, Zhang F et. al.

May 5th, 2021 - Numerous studies have identified impaired decision making (DM) under both ambiguity and risk in adult patients with schizophrenia. However, the assessment of DM in patients with adolescent-onset schizophrenia (AOS) has been challenging as a result...

see more →

News  2,685 results

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness
https://www.medscape.com/viewarticle/950613

May 4th, 2021 - An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-co...

Non-Pharma Approach a Potential 'Game Changer' in Schizophrenia?
https://www.medscape.com/viewarticle/950181

Apr 28th, 2021 - Cognitive remediation (CR), a therapy that encompasses nonpharmacologic approaches to improving cognitive function for patients with severe mental illness, may lead to significant improvement for patients with schizophrenia, new research suggests....

Potential First-in-Class Schizophrenia Drug Cuts Negative Symptoms
https://www.medscape.com/viewarticle/950059

Apr 26th, 2021 - The novel antipsychotic agent SEP-363856 (Sunovion Pharmaceuticals) has a significant and ongoing effect on negative symptoms in patients with schizophrenia, new research shows. Results of a phase 2 placebo-controlled trial show SEP-363856 signifi...

Fast Five Quiz: Schizophrenia Comorbidities
https://reference.medscape.com/viewarticle/947181

Apr 21st, 2021 - Schizophrenia is a serious and persistent brain disorder that causes significant alterations in thoughts, feelings, perceptions, and behavior. It is characterized by heterogeneous positive and negative symptom constellations that interfere with a ...

Nondopamine Antipsychotic Shows Clinical Signal in PD Psychosis
https://www.medscape.com/viewarticle/949776

Apr 21st, 2021 - SEP-363856, an investigational nondopamine antipsychotic that's been the focus of a trial in schizophrenia, has shown signals that it may improve psychosis symptoms in patients with Parkinson's disease without worsening motor symptoms, according t...

see more →

Patient Education  33 results see all →